Autologous Stem Cell Transplantation for Crohn’s Disease
The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in patients with severe Crohn’s disease.
Initiated by the UPMC Immune Transplant and Therapy Center.
This trial is open to pediatric and adult patients between the ages 10 and 60. For additional requirements and criteria please visit ClinicalTrials.gov.
Study Start Date: June 26, 2012
Estimated Primary Completion Date: December 2019
Estimated Study Completion Date: December 2020
Learn more about this trial on its clinicaltrials.gov page or contact Shawna McIntyre, BSN, RN, at email@example.com or 412-692-5552.
Paul Szabolcs, MD
Mounzer Agha, MD
David Binion, MD
Annie Im, MD
David Keljo, MD